Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Strong Sell at Zacks Research

Key Points

• Zacks Research downgraded Supernus Pharmaceuticals to “strong sell” from “hold,” contrasting with a consensus “hold” rating and an average analyst price target of $62.83.
• Supernus shares opened at $42.83, near their 52-week low of $40.51, while the company’s latest quarterly results missed EPS expectations by $1.43 despite revenue of $219.06 million, up 32.4% year over year.
• Analyst sentiment remains mixed: four analysts rate the stock a buy, one a hold, and two a sell; Cantor Fitzgerald recently raised its price target to $67 and maintained an “overweight” rating.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research report issued on Monday, Zacks reports.

A number of other research analysts have also commented on SUPN. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $62.83.

Supernus Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:SUPN opened at $42.83 on Monday. Supernus Pharmaceuticals has a 1 year low of $40.51 and a 1 year high of $59.68. The firm has a fifty day moving average price of $44.49 and a 200 day moving average price of $46.83. The stock has a market capitalization of $2.49 billion, a PE ratio of -22.31, a P/E/G ratio of 0.79 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same period in the prior year, the company posted $0.40 earnings per share. Supernus Pharmaceuticals's quarterly revenue was up 32.4% on a year-over-year basis. On average, sell-side analysts forecast that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds have recently modified their holdings of SUPN. Juncture Wealth Strategies LLC lifted its holdings in Supernus Pharmaceuticals by 5.8% during the third quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company's stock worth $292,000 after acquiring an additional 374 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Supernus Pharmaceuticals by 47.2% during the third quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company's stock worth $65,000 after purchasing an additional 482 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $1,119,000. Allworth Financial LP increased its position in shares of Supernus Pharmaceuticals by 8.8% during the 2nd quarter. Allworth Financial LP now owns 50,669 shares of the specialty pharmaceutical company's stock worth $2,357,000 after purchasing an additional 4,111 shares during the last quarter. Finally, Nykredit A S bought a new stake in Supernus Pharmaceuticals during the second quarter worth $110,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company's portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.